Skip to content
Home
About
Team
Our Board
Management Team
Clinical Ambassadors
Corporate Governance
Our Name & Brandmark
Care Delivery
Pax Centre
Emerald Clinics
Maritime Health Clinic
Drug and Therapy Development
Psychedelic-Assisted Therapy
Ultra-Pure CBD Medicines
MDMA-inspired Medicines
Research & Data Programs
Investor Hub
Shareholder Communications
News
General News
Blogs
Publications
Investor Updates
In the Media
Contact
Menu
Home
About
Team
Our Board
Management Team
Clinical Ambassadors
Corporate Governance
Our Name & Brandmark
Care Delivery
Pax Centre
Emerald Clinics
Maritime Health Clinic
Drug and Therapy Development
Psychedelic-Assisted Therapy
Ultra-Pure CBD Medicines
MDMA-inspired Medicines
Research & Data Programs
Investor Hub
Shareholder Communications
News
General News
Blogs
Publications
Investor Updates
In the Media
Contact
Investor Updates
April 3, 2023
Aspen Australia & Emyria Agreement for EMD-RX5
March 19, 2023
MDMA Analogue Library Expands to Address Mental Health Disorders
March 6, 2023
Emyria partners with Pax Centre for MDMA-assisted therapy
January 12, 2023
Emyria receives $2m+ R&D tax incentive refund
December 14, 2022
Watch the video – Planet Microcap Showcase Presentation
December 6, 2022
December 7 & 8 Webinars
December 1, 2022
Emyria Company Update – December 2022
November 27, 2022
Emyria accepted into National Institutes of Health Preclinical Screening Platform for Pain program
October 17, 2022
MDMA Webinar recording
September 19, 2022
Emyria commences US preclinical program with PsychoGenics
Load More
Search
Search
Search
Blogs
General News
In the Media
Information
Investor Updates
Publications
Uncategorised
